EUROPE INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026
KEY FINDINGS
Europe infertility testing and treatment market captured the highest revenue share of the global market in 2017 by generating $6190.90 million. The market is expected to lead throughout the forecast period of 2018-2026, by exhibiting a CAGR of 6.12% and collecting a net total of $10494.53 million.
MARKET INSIGHTS
Globally, Europe is the largest market for infertility. Although the U.K market accounted for a dominant market share in 2017, other countries such as Germany, Spain, France, Nordics and Russia are fast catching up. In fact, the Nordics are expected to showcase the highest CAGR over the forecast period. The Nordic region has been a destination for fertility tourism for most couples from Europe, North America, Kenya and Hong Kong. The German infertility testing and treatment is the second fastest growing market in Europe. Increasing success rates of the IVF treatments within the region has led to significant growth in this market.
COMPETITIVE INSIGHTS
Companies like Integrated Genetics, Thermo Fisher Scientific Inc, Ovascience, Esco Micro Pte. Ltd, Halotech DNA, Genea, Roche, Irvine Scientific, Ferring Pharmaceuticals, The Cooper Companies Inc, Quest Diagnostic, Origio, Illumina Inc, Andrology Solutions, Vitrolife Ab, Centogene, Celmatrix, Merck, Elucigene, LabCorp and Endo Pharmaceuticals are well established in this region.
Europe infertility testing and treatment market captured the highest revenue share of the global market in 2017 by generating $6190.90 million. The market is expected to lead throughout the forecast period of 2018-2026, by exhibiting a CAGR of 6.12% and collecting a net total of $10494.53 million.
MARKET INSIGHTS
Globally, Europe is the largest market for infertility. Although the U.K market accounted for a dominant market share in 2017, other countries such as Germany, Spain, France, Nordics and Russia are fast catching up. In fact, the Nordics are expected to showcase the highest CAGR over the forecast period. The Nordic region has been a destination for fertility tourism for most couples from Europe, North America, Kenya and Hong Kong. The German infertility testing and treatment is the second fastest growing market in Europe. Increasing success rates of the IVF treatments within the region has led to significant growth in this market.
COMPETITIVE INSIGHTS
Companies like Integrated Genetics, Thermo Fisher Scientific Inc, Ovascience, Esco Micro Pte. Ltd, Halotech DNA, Genea, Roche, Irvine Scientific, Ferring Pharmaceuticals, The Cooper Companies Inc, Quest Diagnostic, Origio, Illumina Inc, Andrology Solutions, Vitrolife Ab, Centogene, Celmatrix, Merck, Elucigene, LabCorp and Endo Pharmaceuticals are well established in this region.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE IS THE LARGEST MARKET
3.2.2. IVF DOMINATES THE FEMALE TREATMENT MARKET
3.2.3. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. MARKET DRIVERS AND IMPACT
4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
4.2.2. MEDICAL TOURISM IN FERTILITY TREATMENTS
4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED FERTILITY TREATMENT
4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
4.2.6. HEALTHIER DONOR EGGS
4.2.7. INTRODUCTION OF NEW TESTING DEVICES
4.3. RESTRAINTS AND IMPACT
4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS INVOLVED
4.3.2. COUNTRY-WISE REGULATORY ISSUES
4.4. MARKET OPPORTUNITIES
4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST
4.5. MARKET CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. PERILS OF MULTIPLE PREGNANCIES
4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE FOR INFERTILITY TREATMENTS
4.5.3.1. DIET AND SUPPLEMENTS
4.5.3.2. ACUPUNCTURE
4.5.3.3. THERAPY
4.5.3.4. QIGONG
5. INFERTILITY CAUSES
5.1. CAUSES OF MALE INFERTILITY
5.1.1. ABNORMALITY IN THE SPERM
5.1.2. ENVIRONMENTAL FACTORS
5.1.3. POOR HEALTH AND LIFESTYLE
5.2. CAUSES OF FEMALE INFERTILITY
5.2.1. OVULATION DISORDERS
5.2.2. DAMAGE TO FALLOPIAN TUBES
5.3. MORAL QUESTIONS
6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
6.1. MARKET BY MALE INFERTILITY TESTING
6.1.1. DNA FRAGMENTATION
6.1.2. OXIDATIVE STRESS ANALYSIS
6.1.3. SPERM PENETRATION ASSAY
6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)
6.1.5. SPERM AGGLUTINATION
6.1.6. MICROSCOPIC EXAMINATION
6.1.7. OTHERS
6.2. MARKET BY MALE INFERTILITY TREATMENT
6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)
6.2.2. SPERM RETRIEVAL TREATMENT
6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)
6.2.4. TESTICULAR SPERM EXTRACTION (TESE)
6.2.5. VARICOCELE REPAIRS
6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)
6.2.7. INTRAUTERINE INSEMINATION (IUI)
6.2.8. IN VITRO FERTILIZATION (IVF)
6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
7.1. MARKET BY FEMALE INFERTILITY TESTING
7.1.1. OVULATION TESTING
7.1.2. HYSTEROSALPINGOGRAPHY
7.1.3. LAPAROSCOPY
7.1.4. TRANSVAGINAL ULTRASOUND
7.1.5. OVARIAN RESERVE TESTING
7.1.6. HORMONAL LEVEL TESTING
7.1.7. OTHERS (GENETIC TESTING)
7.2. MARKET BY FEMALE INFERTILITY TREATMENT
7.2.1. IN VITRO FERTILIZATION
7.2.2. INTRAUTERINE INSEMINATION (IUI)
7.2.3. DRUG AND HORMONE THERAPIES
8. EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)
8.1. FERTILITY AND SURGICAL CENTERS
8.2. HOSPITALS AND RESEARCH LABORATORIES
8.3. CRYOBANKS
9. KEY ANALYTICS
9.1. PORTERS 5 FORCE MODEL
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE PRODUCTS
9.1.3. BARGAINING POWER OF BUYERS
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. INTENSITY OF COMPETITIVE RIVALRY
9.2. VALUE CHAIN ANALYSIS
9.2.1. RAW MATERIAL PROCUREMENT
9.2.2. MANUFACTURING
9.2.3. SUPPLY LOGISTICS
9.2.4. DISTRIBUTION CHANNELS
9.2.5. END USERS
9.3. KEY BUYING CRITERIA
9.3.1. TREATMENT OPTIONS
9.3.2. QUALITY OF MEDICAL PROCEDURES
9.3.3. PRICE OF TREATMENTS
9.3.4. SHIFT TOWARDS MEDICAL TOURISM
9.3.5. REIMBURSEMENT
9.4. REGULATORY FRAMEWORK
9.5. KEY TRENDS
9.5.1. MALE INFERTILITY TREATMENT SEGMENT IS RISING
9.5.2. FERTILITY TOURISM- AN IMPORTANT TREND
9.5.3. UPPER MIDDLE INCOME GROUP IS THE KEY TARGET
9.5.4. REGULATORY ENVIRONMENT KEY MARKET ENABLER
9.5.5. MORE COUPLES OPTING FOR SURROGACY
9.5.6. TECHNOLOGY ENABLING THE SUCCESS OF FERTILITY TREATMENTS
9.6. VENDOR LANDSCAPE
9.7. OPPORTUNITY MATRIX
10. KEY ANALYTICS – TESTING MARKET
10.1. PORTER’S 5 FORCE ANALYSIS
10.1.1. THREAT OF NEW ENTRANTS
10.1.2. THREAT OF SUBSTITUTE PRODUCTS
10.1.3. BARGAINING POWER OF BUYERS
10.1.4. BARGAINING POWER OF SUPPLIERS
10.1.5. INTENSITY OF COMPETITIVE RIVALRY
10.2. KEY BUYING CRITERIA
10.3. VENDOR LANDSCAPE
10.4. OPPORTUNITY MATRIX
11. EUROPE INFERTILITY TESTING AND TREATMENT MARKET COUNTRY ANALYSIS 2018-2026 ($ MILLION)
11.1. UK
11.2. GERMANY
11.3. FRANCE
11.4. NORDICS
11.5. RUSSIA
12. COMPETITIVE ANALYSIS
12.1. ANDROLOGY SOLUTIONS
12.1.1. OVERVIEW
12.1.2. PRODUCT PORTFOLIO
12.1.3. SCOT ANALYSIS
12.2. ENDO PHARMACEUTICALS
12.2.1. OVERVIEW
12.2.2. PRODUCT PORTFOLIO
12.2.3. STRATEGIC MOVES
12.2.4. SCOT ANALYSIS
12.3. PROGYNY
12.3.1. OVERVIEW
12.3.2. PRODUCT PORTFOLIO
12.3.3. STRATEGIC MOVES
12.3.4. SCOT ANALYSIS
12.4. FERRING PHARMACEUTICALS
12.4.1. OVERVIEW
12.4.2. PRODUCT PORTFOLIO
12.4.3. STRATEGIC MOVES
12.4.4. SCOT ANALYSIS
12.5. GENEA
12.5.1. OVERVIEW
12.5.2. PRODUCT PORTFOLIO
12.5.3. STRATEGIC MOVES
12.5.4. SCOT ANALYSIS
12.6. HALOTECH DNA
12.6.1. OVERVIEW
12.6.2. PRODUCT PORTFOLIO
12.6.3. STRATEGIC MOVES
12.6.4. SCOT ANALYSIS
12.7. IRVINE SCIENTIFIC
12.7.1. OVERVIEW
12.7.2. PRODUCT PORTFOLIO
12.7.3. STRATEGIC MOVES
12.7.4. SCOT ANALYSIS
12.8. MERCK
12.8.1. OVERVIEW
12.8.2. PRODUCT PORTFOLIO
12.8.3. STRATEGIC MOVES
12.8.4. SCOT ANALYSIS
12.9. ORIGIO
12.9.1. OVERVIEW
12.9.2. PRODUCT PORTFOLIO
12.9.3. STRATEGIC MOVES
12.9.4. SCOT ANALYSIS
12.10. OVASCIENCE
12.10.1. OVERVIEW
12.10.2. PRODUCT PORTFOLIO
12.10.3. STRATEGIC MOVES
12.10.4. SCOT ANALYSIS
12.11. VITROLIFE AB
12.11.1. OVERVIEW
12.11.2. PRODUCT PORTFOLIO
12.11.3. STRATEGIC MOVES
12.11.4. SCOT ANALYSIS
12.12. THERMO FISHER SCIENTIFIC INC
12.12.1. OVERVIEW
12.12.2. PRODUCT PORTFOLIO
12.12.3. STRATEGIC MOVES
12.12.4. SCOT ANALYSIS
12.13. THE COOPER COMPANIES, INC
12.13.1. OVERVIEW
12.13.2. PRODUCT PORTFOLIO
12.13.3. STRATEGIC MOVES
12.13.4. SCOT ANALYSIS
12.14. QUEST DIAGNOSTIC
12.14.1. OVERVIEW
12.14.2. PRODUCT PORTFOLIO
12.14.3. SCOT ANALYSIS
12.14.4. STRATEGIC MOVES
12.15. ESCO MICRO PTE. LTD.
12.15.1. OVERVIEW
12.15.2. PRODUCT PORTFOLIO
12.15.3. STRATEGIC MOVES
12.15.4. SCOT ANALYSIS
12.16. ELUCIGENE
12.16.1. OVERVIEW
12.16.2. PRODUCT PORTFOLIO
12.16.3. SCOT ANALYSIS
12.16.4. STRATEGIC INITIATIVE
12.17. ALERE
12.17.1. OVERVIEW
12.17.2. PRODUCT PORTFOLIO
12.17.3. SCOT ANALYSIS
12.17.4. STRATEGIC INITIATIVE
12.18. CELMATRIX
12.18.1. OVERVIEW
12.18.2. PRODUCT PORTFOLIO
12.18.3. SCOT ANALYSIS
12.18.4. STRATEGIC INITIATIVE
12.19. VERITAS GENETICS
12.19.1. OVERVIEW
12.19.2. PRODUCT PORTFOLIO
12.19.3. SCOT ANALYSIS
12.19.4. STRATEGIC INITIATIVE
12.20. CLARITAS GENOMICS
12.20.1. OVERVIEW
12.20.2. PRODUCT PORTFOLIO
12.20.3. SCOT ANALYSIS
12.20.4. STRATEGIC INITIATIVE
12.21. ROCHE
12.21.1. OVERVIEW
12.21.2. PRODUCT PORTFOLIO
12.21.3. SCOT ANALYSIS
12.21.4. STRATEGIC INITIATIVE
12.22. LABCORP
12.22.1. OVERVIEW
12.22.2. PRODUCT PORTFOLIO
12.22.3. SCOT ANALYSIS
12.22.4. STRATEGIC INITIATIVE
12.23. AGILENT
12.23.1. OVERVIEW
12.23.2. PRODUCT PORTFOLIO
12.23.3. SCOT ANALYSIS
12.23.4. STRATEGIC INITIATIVE
12.24. INTEGRATED GENETICS
12.24.1. OVERVIEW
12.24.2. PRODUCT PORTFOLIO
12.24.3. SCOT ANALYSIS
12.25. PHOSPHORUS DIAGNOSTICS
12.25.1. OVERVIEW
12.25.2. PRODUCT PORTFOLIO
12.25.3. SCOT ANALYSIS
12.25.4. STRATEGIC INITIATIVE
12.26. CENTOGENE
12.26.1. OVERVIEW
12.26.2. PRODUCT PORTFOLIO
12.26.3. SCOT ANALYSIS
12.26.4. STRATEGIC INITIATIVE
12.27. NATERA INC
12.27.1. OVERVIEW
12.27.2. PRODUCT PORTFOLIO
12.27.3. SCOT ANALYSIS
12.27.4. STRATEGIC INITIATIVE
12.28. ILLUMINA INC
12.28.1. OVERVIEW
12.28.2. PRODUCT PORTFOLIO
12.28.3. SCOT ANALYSIS
12.28.4. STRATEGIC INITIATIVE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE IS THE LARGEST MARKET
3.2.2. IVF DOMINATES THE FEMALE TREATMENT MARKET
3.2.3. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET
4. MARKET OVERVIEW
4.1. MARKET DEFINITION
4.2. MARKET DRIVERS AND IMPACT
4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
4.2.2. MEDICAL TOURISM IN FERTILITY TREATMENTS
4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED FERTILITY TREATMENT
4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
4.2.6. HEALTHIER DONOR EGGS
4.2.7. INTRODUCTION OF NEW TESTING DEVICES
4.3. RESTRAINTS AND IMPACT
4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS INVOLVED
4.3.2. COUNTRY-WISE REGULATORY ISSUES
4.4. MARKET OPPORTUNITIES
4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST
4.5. MARKET CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. PERILS OF MULTIPLE PREGNANCIES
4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE FOR INFERTILITY TREATMENTS
4.5.3.1. DIET AND SUPPLEMENTS
4.5.3.2. ACUPUNCTURE
4.5.3.3. THERAPY
4.5.3.4. QIGONG
5. INFERTILITY CAUSES
5.1. CAUSES OF MALE INFERTILITY
5.1.1. ABNORMALITY IN THE SPERM
5.1.2. ENVIRONMENTAL FACTORS
5.1.3. POOR HEALTH AND LIFESTYLE
5.2. CAUSES OF FEMALE INFERTILITY
5.2.1. OVULATION DISORDERS
5.2.2. DAMAGE TO FALLOPIAN TUBES
5.3. MORAL QUESTIONS
6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
6.1. MARKET BY MALE INFERTILITY TESTING
6.1.1. DNA FRAGMENTATION
6.1.2. OXIDATIVE STRESS ANALYSIS
6.1.3. SPERM PENETRATION ASSAY
6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)
6.1.5. SPERM AGGLUTINATION
6.1.6. MICROSCOPIC EXAMINATION
6.1.7. OTHERS
6.2. MARKET BY MALE INFERTILITY TREATMENT
6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)
6.2.2. SPERM RETRIEVAL TREATMENT
6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)
6.2.4. TESTICULAR SPERM EXTRACTION (TESE)
6.2.5. VARICOCELE REPAIRS
6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)
6.2.7. INTRAUTERINE INSEMINATION (IUI)
6.2.8. IN VITRO FERTILIZATION (IVF)
6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
7.1. MARKET BY FEMALE INFERTILITY TESTING
7.1.1. OVULATION TESTING
7.1.2. HYSTEROSALPINGOGRAPHY
7.1.3. LAPAROSCOPY
7.1.4. TRANSVAGINAL ULTRASOUND
7.1.5. OVARIAN RESERVE TESTING
7.1.6. HORMONAL LEVEL TESTING
7.1.7. OTHERS (GENETIC TESTING)
7.2. MARKET BY FEMALE INFERTILITY TREATMENT
7.2.1. IN VITRO FERTILIZATION
7.2.2. INTRAUTERINE INSEMINATION (IUI)
7.2.3. DRUG AND HORMONE THERAPIES
8. EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)
8.1. FERTILITY AND SURGICAL CENTERS
8.2. HOSPITALS AND RESEARCH LABORATORIES
8.3. CRYOBANKS
9. KEY ANALYTICS
9.1. PORTERS 5 FORCE MODEL
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE PRODUCTS
9.1.3. BARGAINING POWER OF BUYERS
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. INTENSITY OF COMPETITIVE RIVALRY
9.2. VALUE CHAIN ANALYSIS
9.2.1. RAW MATERIAL PROCUREMENT
9.2.2. MANUFACTURING
9.2.3. SUPPLY LOGISTICS
9.2.4. DISTRIBUTION CHANNELS
9.2.5. END USERS
9.3. KEY BUYING CRITERIA
9.3.1. TREATMENT OPTIONS
9.3.2. QUALITY OF MEDICAL PROCEDURES
9.3.3. PRICE OF TREATMENTS
9.3.4. SHIFT TOWARDS MEDICAL TOURISM
9.3.5. REIMBURSEMENT
9.4. REGULATORY FRAMEWORK
9.5. KEY TRENDS
9.5.1. MALE INFERTILITY TREATMENT SEGMENT IS RISING
9.5.2. FERTILITY TOURISM- AN IMPORTANT TREND
9.5.3. UPPER MIDDLE INCOME GROUP IS THE KEY TARGET
9.5.4. REGULATORY ENVIRONMENT KEY MARKET ENABLER
9.5.5. MORE COUPLES OPTING FOR SURROGACY
9.5.6. TECHNOLOGY ENABLING THE SUCCESS OF FERTILITY TREATMENTS
9.6. VENDOR LANDSCAPE
9.7. OPPORTUNITY MATRIX
10. KEY ANALYTICS – TESTING MARKET
10.1. PORTER’S 5 FORCE ANALYSIS
10.1.1. THREAT OF NEW ENTRANTS
10.1.2. THREAT OF SUBSTITUTE PRODUCTS
10.1.3. BARGAINING POWER OF BUYERS
10.1.4. BARGAINING POWER OF SUPPLIERS
10.1.5. INTENSITY OF COMPETITIVE RIVALRY
10.2. KEY BUYING CRITERIA
10.3. VENDOR LANDSCAPE
10.4. OPPORTUNITY MATRIX
11. EUROPE INFERTILITY TESTING AND TREATMENT MARKET COUNTRY ANALYSIS 2018-2026 ($ MILLION)
11.1. UK
11.2. GERMANY
11.3. FRANCE
11.4. NORDICS
11.5. RUSSIA
12. COMPETITIVE ANALYSIS
12.1. ANDROLOGY SOLUTIONS
12.1.1. OVERVIEW
12.1.2. PRODUCT PORTFOLIO
12.1.3. SCOT ANALYSIS
12.2. ENDO PHARMACEUTICALS
12.2.1. OVERVIEW
12.2.2. PRODUCT PORTFOLIO
12.2.3. STRATEGIC MOVES
12.2.4. SCOT ANALYSIS
12.3. PROGYNY
12.3.1. OVERVIEW
12.3.2. PRODUCT PORTFOLIO
12.3.3. STRATEGIC MOVES
12.3.4. SCOT ANALYSIS
12.4. FERRING PHARMACEUTICALS
12.4.1. OVERVIEW
12.4.2. PRODUCT PORTFOLIO
12.4.3. STRATEGIC MOVES
12.4.4. SCOT ANALYSIS
12.5. GENEA
12.5.1. OVERVIEW
12.5.2. PRODUCT PORTFOLIO
12.5.3. STRATEGIC MOVES
12.5.4. SCOT ANALYSIS
12.6. HALOTECH DNA
12.6.1. OVERVIEW
12.6.2. PRODUCT PORTFOLIO
12.6.3. STRATEGIC MOVES
12.6.4. SCOT ANALYSIS
12.7. IRVINE SCIENTIFIC
12.7.1. OVERVIEW
12.7.2. PRODUCT PORTFOLIO
12.7.3. STRATEGIC MOVES
12.7.4. SCOT ANALYSIS
12.8. MERCK
12.8.1. OVERVIEW
12.8.2. PRODUCT PORTFOLIO
12.8.3. STRATEGIC MOVES
12.8.4. SCOT ANALYSIS
12.9. ORIGIO
12.9.1. OVERVIEW
12.9.2. PRODUCT PORTFOLIO
12.9.3. STRATEGIC MOVES
12.9.4. SCOT ANALYSIS
12.10. OVASCIENCE
12.10.1. OVERVIEW
12.10.2. PRODUCT PORTFOLIO
12.10.3. STRATEGIC MOVES
12.10.4. SCOT ANALYSIS
12.11. VITROLIFE AB
12.11.1. OVERVIEW
12.11.2. PRODUCT PORTFOLIO
12.11.3. STRATEGIC MOVES
12.11.4. SCOT ANALYSIS
12.12. THERMO FISHER SCIENTIFIC INC
12.12.1. OVERVIEW
12.12.2. PRODUCT PORTFOLIO
12.12.3. STRATEGIC MOVES
12.12.4. SCOT ANALYSIS
12.13. THE COOPER COMPANIES, INC
12.13.1. OVERVIEW
12.13.2. PRODUCT PORTFOLIO
12.13.3. STRATEGIC MOVES
12.13.4. SCOT ANALYSIS
12.14. QUEST DIAGNOSTIC
12.14.1. OVERVIEW
12.14.2. PRODUCT PORTFOLIO
12.14.3. SCOT ANALYSIS
12.14.4. STRATEGIC MOVES
12.15. ESCO MICRO PTE. LTD.
12.15.1. OVERVIEW
12.15.2. PRODUCT PORTFOLIO
12.15.3. STRATEGIC MOVES
12.15.4. SCOT ANALYSIS
12.16. ELUCIGENE
12.16.1. OVERVIEW
12.16.2. PRODUCT PORTFOLIO
12.16.3. SCOT ANALYSIS
12.16.4. STRATEGIC INITIATIVE
12.17. ALERE
12.17.1. OVERVIEW
12.17.2. PRODUCT PORTFOLIO
12.17.3. SCOT ANALYSIS
12.17.4. STRATEGIC INITIATIVE
12.18. CELMATRIX
12.18.1. OVERVIEW
12.18.2. PRODUCT PORTFOLIO
12.18.3. SCOT ANALYSIS
12.18.4. STRATEGIC INITIATIVE
12.19. VERITAS GENETICS
12.19.1. OVERVIEW
12.19.2. PRODUCT PORTFOLIO
12.19.3. SCOT ANALYSIS
12.19.4. STRATEGIC INITIATIVE
12.20. CLARITAS GENOMICS
12.20.1. OVERVIEW
12.20.2. PRODUCT PORTFOLIO
12.20.3. SCOT ANALYSIS
12.20.4. STRATEGIC INITIATIVE
12.21. ROCHE
12.21.1. OVERVIEW
12.21.2. PRODUCT PORTFOLIO
12.21.3. SCOT ANALYSIS
12.21.4. STRATEGIC INITIATIVE
12.22. LABCORP
12.22.1. OVERVIEW
12.22.2. PRODUCT PORTFOLIO
12.22.3. SCOT ANALYSIS
12.22.4. STRATEGIC INITIATIVE
12.23. AGILENT
12.23.1. OVERVIEW
12.23.2. PRODUCT PORTFOLIO
12.23.3. SCOT ANALYSIS
12.23.4. STRATEGIC INITIATIVE
12.24. INTEGRATED GENETICS
12.24.1. OVERVIEW
12.24.2. PRODUCT PORTFOLIO
12.24.3. SCOT ANALYSIS
12.25. PHOSPHORUS DIAGNOSTICS
12.25.1. OVERVIEW
12.25.2. PRODUCT PORTFOLIO
12.25.3. SCOT ANALYSIS
12.25.4. STRATEGIC INITIATIVE
12.26. CENTOGENE
12.26.1. OVERVIEW
12.26.2. PRODUCT PORTFOLIO
12.26.3. SCOT ANALYSIS
12.26.4. STRATEGIC INITIATIVE
12.27. NATERA INC
12.27.1. OVERVIEW
12.27.2. PRODUCT PORTFOLIO
12.27.3. SCOT ANALYSIS
12.27.4. STRATEGIC INITIATIVE
12.28. ILLUMINA INC
12.28.1. OVERVIEW
12.28.2. PRODUCT PORTFOLIO
12.28.3. SCOT ANALYSIS
12.28.4. STRATEGIC INITIATIVE
LIST OF TABLES
TABLE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY GENDER 2018-2026 ($ MILLION)
TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS
TABLE 3 EUROPE MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 4 EUROPE MALE INFERTILITY TESTING MARKET 2018-2026($MILLION)
TABLE 5 PROS AND CONS OF DNA SHARING METHODS
TABLE 6 EUROPE FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 7 EUROPE FEMALE INFERTILITY TESTING MARKET 2018-2026 ($MILLION)
TABLE 8 EUROPE FEMALE INFERTILITY TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 9 AVERAGE COST OF SOME INFERTILITY TREATMENTS
TABLE 10 SOME COMMON DRUG THERAPIES
TABLE 11 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)
TABLE 12 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($MILLION)
TABLE 13 COST OF IVF IN RUSSIA
TABLE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY GENDER 2018-2026 ($ MILLION)
TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS
TABLE 3 EUROPE MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 4 EUROPE MALE INFERTILITY TESTING MARKET 2018-2026($MILLION)
TABLE 5 PROS AND CONS OF DNA SHARING METHODS
TABLE 6 EUROPE FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 7 EUROPE FEMALE INFERTILITY TESTING MARKET 2018-2026 ($MILLION)
TABLE 8 EUROPE FEMALE INFERTILITY TREATMENT MARKET 2018-2026 ($ MILLION)
TABLE 9 AVERAGE COST OF SOME INFERTILITY TREATMENTS
TABLE 10 SOME COMMON DRUG THERAPIES
TABLE 11 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 ($ MILLION)
TABLE 12 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 ($MILLION)
TABLE 13 COST OF IVF IN RUSSIA
LIST OF FIGURES
FIGURE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING
FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN
FIGURE 4 RATE OF MULTIPLE DELIVERIES
FIGURE 5 CAUSES OF INFERTILITY
FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER
FIGURE 7 CAUSES OF SPERM DNA FRAGMENTATION
FIGURE 8 UK INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 9 FERTILITY TREATMENT IN 2014
FIGURE 10 GERMANY INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 11 FRANCE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 12 NORDICS INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 13 RUSSIA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
COMPANIES MENTIONED
1. ANDROLOGY SOLUTIONS
2. ENDO PHARMACEUTICALS
3. PROGYNY
4. FERRING PHARMACEUTICALS
5. GENEA
6. HALOTECH DNA
7. IRVINE SCIENTIFIC
8. MERCK
9. ORIGIO
10. OVASCIENCE
11. VITROLIFE AB
12. THERMO FISHER SCIENTIFIC INC
13. THE COOPER COMPANIES, INC
14. QUEST DIAGNOSTIC
15. ESCO MICRO PTE. LTD.
16. ELUCIGENE
17. ALERE
18. CELMATRIX
19. VERITAS GENETICS
20. CLARITAS GENOMICS
21. ROCHE
22. LABCORP
23. AGILENT
24. INTEGRATED GENETICS
25. PHOSPHORUS DIAGNOSTICS
26. CENTOGENE
.27. NATERA INC
28. ILLUMINA INC
FIGURE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($ MILLION)
FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING
FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN
FIGURE 4 RATE OF MULTIPLE DELIVERIES
FIGURE 5 CAUSES OF INFERTILITY
FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER
FIGURE 7 CAUSES OF SPERM DNA FRAGMENTATION
FIGURE 8 UK INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 9 FERTILITY TREATMENT IN 2014
FIGURE 10 GERMANY INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 11 FRANCE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 12 NORDICS INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
FIGURE 13 RUSSIA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 ($MILLION)
COMPANIES MENTIONED
1. ANDROLOGY SOLUTIONS
2. ENDO PHARMACEUTICALS
3. PROGYNY
4. FERRING PHARMACEUTICALS
5. GENEA
6. HALOTECH DNA
7. IRVINE SCIENTIFIC
8. MERCK
9. ORIGIO
10. OVASCIENCE
11. VITROLIFE AB
12. THERMO FISHER SCIENTIFIC INC
13. THE COOPER COMPANIES, INC
14. QUEST DIAGNOSTIC
15. ESCO MICRO PTE. LTD.
16. ELUCIGENE
17. ALERE
18. CELMATRIX
19. VERITAS GENETICS
20. CLARITAS GENOMICS
21. ROCHE
22. LABCORP
23. AGILENT
24. INTEGRATED GENETICS
25. PHOSPHORUS DIAGNOSTICS
26. CENTOGENE
.27. NATERA INC
28. ILLUMINA INC
